Notice to the Annual General Meeting of Biovitrum AB (publ), Tuesday April 27, 2010

Biovitrum AB (publ) announces by issuing of a press release the content of the
notice to the Annual General Meeting 2010.

Attachment:
- Notice to the Annual General Meeting 2010 of Biovitrum AB (publ)

For further information please contact:

Martin Nicklasson, CEO
Phone: +46 8 697 20 00

Göran Arvidson, CFO
Cell phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations
Cell phone: +46 73 422 15 40
erik.kinnman@biovitrum.com <mailto:erik.kinnman@biovitrum.com>

About Swedish Orphan Biovitrum
On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish
Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading
company focused on treatment of rare diseases.

Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company
with an international market presence. The company is focused on providing and
developing orphan and niche specialist pharmaceuticals to patients with high
medical needs. The portfolio consists of about 60 marketed products and an
emerging late stage clinical development pipeline within rare diseases. Swedish
Orphan Biovitrum has pro-forma revenues 2009 of about 2 BSEK and approximately
500 employees. The head office is located in Sweden and the share (STO: BVT) is
listed on NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com <http://www.biovitrum.com/>.

The above information has been made public in accordance with the Securities
Market Act and/or the Financial Instruments Trading Act. The information was
published at 8.30 a.m. CET on March 26, 2010.